Tracer library / [177Lu]Lu-LNC1011

[177Lu]Lu-LNC1011

Also written as [Lu-177]Lu-LNC1011

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: Clinical research
Syntheses indexed: 0

Prostate cancer Dosimetry and biodistribution studies PSMA-directed radioligand therapy

What it is

Compound class: PSMA-targeted radioligand (dansylated amino acid-modified albumin-binding PSMA urea derivative)
Target / mechanism: Prostate-specific membrane antigen (PSMA) PMID 40113222
Clinical application: Metastatic castration-resistant prostate cancer PMID 40208314
Theranostic pair: —

Published syntheses

No synthesis has been parsed for this agent yet.

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

PSMA-targeted radioligand therapy with [177Lu]Lu-LNC1011 for metastatic castration-resistant prostate cancer: a pilot study.
2025 · Eur J Nucl Med Mol Imaging · Clinical study

Need this precursor?We can point you to suppliers for [177Lu]Lu-LNC1011, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 39 from PMID 40208314: 'Eight mCRPC patients who met the inclusion criteria received intravenous treatment with [177Lu]Lu-LNC1011.'.